Overview
No overview information available.
Indication
主要用于消化不良以及场内异常发酵,小儿饮食不当引起的腹泻及营养不良等;也用于使用抗生素及放、化疗后引起的菌群失调性腹泻及急性肠胃炎、腹泻、痢疾等。
Associated Conditions
No associated conditions information available.
Research Report
Lactobacillus as a Therapeutic Agent: A Comprehensive Clinical and Microbiological Review
Section 1: The Lactobacillus Genus: Foundational Biology and Evolving Taxonomy
This section establishes the fundamental biological identity of [Lactobacillus] and addresses the recent, significant shift in its taxonomy, a crucial framework for interpreting the scientific and clinical research discussed in this report.
1.1 Core Biological and Metabolic Characteristics
[Lactobacillus] is a genus of Gram-positive, rod-shaped, non-spore-forming bacteria belonging to the phylum Firmicutes.[1] They are typically catalase-negative, facultatively anaerobic or microaerophilic, meaning they can thrive in environments with little to no oxygen.[1] A key characteristic is their high tolerance for acidic conditions, which is fundamental to their role in fermented foods and their ability to survive transit through the low pH environment of the human stomach to reach the intestines.[3]
The defining feature of the genus is its metabolism of carbohydrates to produce lactic acid, making it the largest and most prominent group within the Lactic Acid Bacteria (LAB).[1] Based on their metabolic pathways and end-products, lactobacilli are traditionally divided into three functional groups [1]:
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
---|---|---|---|---|---|
2025/08/27 | Not Applicable | Completed | Dharmais National Cancer Center Hospital | ||
2025/03/12 | Not Applicable | Active, not recruiting | Chang Gung Memorial Hospital | ||
2024/08/19 | Phase 2 | ENROLLING_BY_INVITATION | National Institute of Pediatrics, Mexico | ||
2024/06/21 | Not Applicable | Recruiting | |||
2023/08/03 | Phase 2 | Recruiting | |||
2023/04/11 | Phase 4 | Recruiting | |||
2023/01/27 | Phase 4 | Completed | |||
2022/10/13 | Phase 3 | Recruiting | |||
2022/06/22 | Phase 2 | Recruiting | |||
2022/02/24 | Phase 1 | UNKNOWN | Dr. Soetomo General Hospital |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
---|---|---|---|---|---|
No FDA approvals found for this drug. |
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
---|---|---|---|
No EMA approvals found for this drug. |
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No HSA approvals found for this drug. |
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
---|---|---|---|---|---|
No NMPA approvals found for this drug. |
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
---|---|---|---|---|---|
No PPB approvals found for this drug. |
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
---|---|---|---|---|---|
NutriVital Premium 50 Billion Probiotic + | 281598 | Medicine | A | 10/21/2016 | |
Pro-Immune | 374155 | Medicine | A | 9/3/2021 | |
Microgenics Probiotic 55 Billion | 308746 | Medicine | A | 8/29/2018 | |
Nature’s Way Restore Probiotic 50 Billion | 352201 | Pharmacare Laboratories Pty Ltd | Medicine | A | 12/23/2020 |
Daily Probiotics Gold | 421716 | Medicine | A | 9/13/2023 | |
Elevit Probiotics Immunity and Gut Health | 374417 | Medicine | A | 9/9/2021 | |
Women's Microflora Probiotic Capsules | 401452 | Medicine | A | 12/21/2022 | |
Healthy Growth + Probiotic Prebiotic | 396714 | Medicine | A | 9/29/2022 | |
Acne Clear + Probiotic | 396250 | Medicine | A | 9/21/2022 | |
UltraLife Probiotics | 389734 | Medicine | A | 6/7/2022 |
Health Canada Drug Approvals
Approved Product | Company | DIN | Dosage Form | Strength | Market Date |
---|---|---|---|---|---|
INTESTALIFE | holista health (canada) inc. | 02232997 | Capsule - Oral | 3.4 B | 8/1/1997 |
FERMALAC ECC 1B | institut rosell inc. | 00351547 | Capsule (Enteric-Coated) - Oral | 0.7 B | 12/31/1960 |
CIMA AEMPS Drug Approvals
Approved Product | Company | Registration Number | Pharmaceutical Form | Prescription Type | Status |
---|---|---|---|---|---|
MUVAGYN 10E8 UFC/10E8 UFC CAPSULAS VAGINALES DURAS | Casen Recordati S.L. | 88680 | CÁPSULA VAGINAL DURA | Sin Receta | Commercialized |
Philippines FDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No Philippines FDA approvals found for this drug. |
Saudi SFDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No Saudi SFDA approvals found for this drug. |
Malaysia NPRA Drug Approvals
Approved Product | Company | Registration Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No Malaysia NPRA approvals found for this drug. |
UK EMC Drug Information
Medicine Name | MA Holder | MA Number | Pharmaceutical Form | Active Ingredient | Authorization Date |
---|---|---|---|---|---|
No UK EMC drug information found for this drug. |
Help Us Improve
Your feedback helps us provide better drug information and insights.